In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Crossing the Canyon in Prostate Cancer

Executive Summary

Cancer drugs are hot. Sales of cancer therapies rose from $2.1 billion to $2.9 billion between 1992 and 1996, and even those figures may understate the market. Moreover, the number of cancer drugs in development has also risen dramatically. Perhaps the most fertile area of opportunity: prostate cancer, which is being boosted by an increase in consumer support, leading to faster FDA approvals, and renewed investment from Big Pharma and biotechs.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts